comparemela.com

Latest Breaking News On - La 167 - Page 1 : comparemela.com

Kelun s Trop2 ADC meets primary endpoints in phase III triple-negative breast cancer trial

Kelun-Biotech Biopharmaceutical Co. Ltd.’s trophoblast cell-surface antigen 2 (Trop2)-targeted antibody-drug conjugate (ADC), SKB-264, met the primary endpoint of progression-free survival (PFS) in a phase III trial in patients with unresectable locally advanced, recurrent or metastatic triple-negative breast cancer (TNBC), according to an interim analysis.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.